61.2 Chronic Pain Syndromes & Chronic Daily Headaches

Neurobiology of Chronic Pain & The Biopsychosocial Model

Chronic pain is defined as pain that persists or recurs for longer than 3 to 6 months, extending beyond the anticipated healing time of damaged tissue. In the United States, chronic pain affects more than 20% of adults and represents a leading driver of disability, depression, and healthcare expenditure. Modern neurobiology conceptualizes chronic pain not as a prolonged symptom of ongoing tissue pathology, but as an independent, maladaptive neurobiological disease process characterized by central sensitization and neuroplastic reorganization.

Taxonomy of Pain Mechanisms

1. Nociceptive Pain: Arises from actual or threatened damage to non-neural tissue and is mediated by normally functioning nociceptive somatosensory receptors (e.g., osteoarthritis, acute trauma, rheumatoid synovitis).
2. Neuropathic Pain: Caused by a primary lesion or disease of the somatosensory nervous system (e.g., painful diabetic neuropathy, postherpetic neuralgia, radiculopathy, central post-stroke pain).
3. Nociplastic Pain: Pain arising from altered nociceptive processing despite no clear evidence of actual or threatened tissue damage or somatosensory system lesion (e.g., fibromyalgia, irritable bowel syndrome, non-specific chronic low back pain).

                  CENTRAL SENSITIZATION: MOLECULAR & SYNAPTIC MECHANISMS

   Repetitive C-Fiber Stimulation ──> Sustained Presynaptic Release of Glutamate & Substance P
                                                      │
                                                      ▼
                                   Prolonged Depolarization of Dorsal Horn Neurons
                                                      │
                                                      ▼
                                  Magnesium (Mg2+) Plug Evicted from NMDA Receptors
                                                      │
                                                      ▼
                                     Massive Intracellular Calcium (Ca2+) Influx
                                                      │
                                                      ▼
                                   Activation of PKC, CaMKII & Intracellular Cascades
                                                      │
                                                      ▼
                                    Long-Term Potentiation (LTP) of Pain Synapses
                                                      │
                     ┌────────────────────────────────┴────────────────────────────────┐
                     ▼                                                                 ▼
             ALLODYNIA (A-β Fibers)                                       SECONDARY HYPERALGESIA
      Non-noxious tactile stimuli evoke pain                        Exaggerated pain response spreads widely
       due to novel synaptic cross-wiring                            beyond initial anatomical injury field

Molecular Pathophysiology of Central Sensitization

Central sensitization represents an operational state of neuronal hyperexcitability within the dorsal horn of the spinal cord and higher cortical projection areas:

• The 'Wind-Up' Phenomenon and NMDA Activation: Under physiological conditions, the N-methyl-D-aspartate (NMDA) receptor channel is tonically blocked by an extracellular magnesium ion ($\text{Mg}^{2+}$). High-frequency, repetitive firing of unmyelinated primary afferent C-fibers releases sustained bursts of glutamate and substance P. These bind to postsynaptic AMPA and neurokinin-1 (NK-1) receptors, producing prolonged membrane depolarization that forcibly expels the $\text{Mg}^{2+}$ plug. This allows unchecked calcium ($\text{Ca}^{2+}$) influx through NMDA channels, initiating intracellular cascades that activate protein kinase C (PKC) and calcium/calmodulin-dependent protein kinase II (CaMKII).
• Synaptic Plasticity & Receptive Field Expansion: Intracellular phosphorylation cascades insert additional AMPA receptors into the postsynaptic membrane (synaptic trafficking), establishing long-term potentiation (LTP) of nociceptive pathways. Consequently, dorsal horn wide dynamic range (WDR) neurons exhibit reduced activation thresholds, exaggerated firing frequencies, and expansion of receptive fields, leading to allodynia (pain elicited by non-painful stimuli) and hyperalgesia (exaggerated pain elicited by painful stimuli).
• Glial Activation & Neuroinflammation: Spinal microglia and astrocytes become activated by fractalkine and ATP. They release pro-inflammatory mediators including IL-1β, TNF-α, and brain-derived neurotrophic factor (BDNF). BDNF downregulates potassium-chloride cotransporters (KCC2) in dorsal horn neurons, reversing the physiological inhibitory action of GABA and glycine, causing disinhibition.
• Failure of Descending Modulation: Endogenous descending analgesic pathways originating in the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) normally suppress spinal nociceptive transmission via norepinephrine and serotonin. In chronic pain states, these descending pathways become exhausted or switch to paradoxical descending facilitation.

Opioid-Induced Hyperalgesia (OIH) vs. Opioid Tolerance

A critical clinical challenge in chronic pain management is distinguishing opioid tolerance from opioid-induced hyperalgesia (OIH):

• Opioid Tolerance: Characterized by a rightward shift of the dose-response curve; the patient requires escalating doses of opioids to achieve the same initial analgesic effect. Increasing the opioid dose temporarily restores analgesia.
• Opioid-Induced Hyperalgesia (OIH): A paradoxical state of neuroplastic nociceptive sensitization caused by exposure to opioids. Patients present with diffuse, ill-defined, spreading pain and generalized cutaneous allodynia that worsens as the opioid dose is escalated. Driven by dynorphin accumulation, activation of spinal NMDA receptors, and microglial release of neuroinflammatory mediators. Management requires cautious downward dose titration or rotation to an NMDA-receptor antagonist agent such as buprenorphine.

                  OPIOID TOLERANCE VS. OPIOID-INDUCED HYPERALGESIA (OIH)

   Feature                  Opioid Tolerance                         Opioid-Induced Hyperalgesia (OIH)
   ══════════════════════════════════════════════════════════════════════════════════════════════════════════
   Mechanism                Downregulation of μ-opioid receptors;    NMDA receptor activation, dynorphin release,
                            uncoupling of Gi/o protein signaling     microglial neuroinflammation
   ──────────────────────────────────────────────────────────────────────────────────────────────────────
   Pain Distribution        Anatomically consistent with original    Diffuse, spreading beyond original site,
                            pathological tissue injury               generalized cutaneous allodynia
   ──────────────────────────────────────────────────────────────────────────────────────────────────────
   Effect of Dose Increase  Temporary improvement in analgesia       PARADOXICAL WORSENING of pain and allodynia
   ──────────────────────────────────────────────────────────────────────────────────────────────────────
   Management Strategy      Rotate opioid or cautiously increase;    GRADUAL OPIOID WEAN; rotate to buprenorphine;
                            add multimodal non-opioid adjuvants      add NMDA antagonists (ketamine)
   ══════════════════════════════════════════════════════════════════════════════════════════════════════════

The Interdisciplinary Biopsychosocial Paradigm

The biopsychosocial framework recognizes that chronic pain is an emergent property of dynamic interactions between biological nociception, affective-emotional states, cognitive evaluations, and socio-environmental factors. Management requires an integrated, multimodal strategy:

1. Physical Rehabilitation: Graded exercise therapy, functional restoration, active stretching, and aquatic therapy to overcome kinesiophobia (fear of movement) and reverse musculoskeletal deconditioning.
2. Behavioral & Psychological Therapies:
   • Cognitive Behavioral Therapy (CBT): Addresses pain catastrophizing, identifies cognitive distortions, and fosters active behavioral coping strategies.
   • Acceptance and Commitment Therapy (ACT): Encourages psychological flexibility and commitment to values-based functional activities regardless of pain intensity.
3. Non-Opioid Pharmacotherapy: Tailored adjuvant agents (SNRIs, gabapentinoids, NSAIDs, topical agents) targeting specific neurochemical pathways.
4. Interventional Modalities: Fluoroscopically guided epidural steroid injections, radiofrequency ablation, or peripheral nerve stimulation as adjuncts to facilitate physical therapy.

---

Chronic Daily Headache (CDH) Spectrum

Chronic Daily Headache (CDH) is an umbrella clinical term applied to headache disorders occurring on $\ge 15\text{ days per month for }>3\text{ consecutive months}$. In primary care, the vast majority of CDH cases fall into three distinct clinical entities: Chronic Migraine, Chronic Tension-Type Headache, and Medication-Overuse Headache.

                  DIAGNOSTIC CRITERIA & FEATURES OF CHRONIC DAILY HEADACHES

   Headache Subtype        Frequency & Duration                  Clinical Phenotype & Associated Features
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Chronic Migraine        >= 15 days/month for > 3 months;      Unilateral or bilateral, pulsating/throbbing,
                           on >= 8 days/month fulfills criteria  moderate-to-severe, aggravated by routine physical
                           for migraine or responds to triptan   activity; nausea, vomiting, photophobia, phonophobia.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Chronic Tension-Type    >= 15 days/month for > 3 months       Bilateral, pressing/tightening ('band-like'),
   Headache (CTTH)         (average >= 180 days/year)            mild-to-moderate intensity; NO aggravation with
                                                                 activity; NO nausea/vomiting; at most one of
                                                                 photophobia or phonophobia.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Medication-Overuse      >= 15 days/month in patient with      Refractory, daily, holocephalic morning headache;
   Headache (MOH)          pre-existing headache disorder;       develops secondary to chronic overuse of acute abortive
                           regular medication overuse for        medications (triptans/opioids >= 10 days/month;
                           > 3 consecutive months                simple analgesics >= 15 days/month).
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Chronic Migraine

• Pathophysiology: Chronic migraine evolves from episodic migraine via progressive sensitization of the trigeminovascular system. Sensory fibers from the ophthalmic division of the trigeminal nerve (CN V1) innervate the dural vasculature. Activation triggers perivascular release of vasoactive neuropeptides—predominantly Calcitonin Gene-Related Peptide (CGRP), substance P, and neurokinin A. CGRP causes profound cerebral vasodilation, mast cell degranulation, plasma protein extravasation, and sterile neurogenic inflammation, driving central sensitization of second-order trigeminocervical neurons.
• Preventive Pharmacotherapies:
  • Topiramate: 25 mg daily, titrated weekly by 25-50 mg to a target dose of 50 mg twice daily (100 mg/day). Mechanism: blocks voltage-dependent sodium channels, potentiates GABA, and antagonizes AMPA/kainate receptors. High-yield side effects: paresthesias, weight loss, anorexia, cognitive slowing ('Dopamax' / word-finding difficulty), nephrolithiasis, metabolic acidosis via carbonic anhydrase inhibition, and teratogenicity (cleft lip/palate).
  • Beta-Blockers: Propranolol (80-240 mg/day extended-release) or Metoprolol (100-200 mg/day). First-line in young, healthy, or hypertensive patients. Contraindicated in moderate-to-severe asthma, bradycardia, or high-grade AV conduction block.
  • Tricyclic Antidepressants: Amitriptyline (10-75 mg at bedtime). Enhances descending monoaminergic inhibition. Excellent for patients with comorbid insomnia or chronic tension headache. Avoid in older adults per Beers criteria.
  • Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies:
    • Erenumab: Targets the canonical CGRP receptor (70-140 mg subcutaneously monthly).
    • Fremanezumab, Galcanezumab, Eptinezumab (IV): Target the CGRP ligand directly.
    • Well-tolerated, devoid of hepatorenal toxicity; common side effects include injection-site reactions and constipation (especially erenumab).
  • OnabotulinumtoxinA (Botox) Injections:
    • FDA-approved specifically for Chronic Migraine (ineffective for episodic migraine or tension headaches).
    • PREEMPT injection protocol: 155 Units distributed across 31 standardized anatomical injection sites covering 7 head and neck muscle groups (corrugator, procerus, frontalis, temporalis, occipitalis, cervical paraspinal, and trapezius) administered every 12 weeks.

2. Chronic Tension-Type Headache (CTTH)

• Clinical Presentation: Bilateral, dull, aching, non-pulsatile pain with a pressing or tightening quality described as a 'vice' or 'tight band' around the cranium. Intensity is mild to moderate and does not prevent normal daily activities. Physical activity does not aggravate the headache. Nausea and vomiting are absent. Either photophobia or phonophobia may be present, but not both.
• Management: The first-line evidence-based pharmacologic preventive agent is Amitriptyline (titrated from 10 mg to 50-75 mg at bedtime). Non-pharmacologic modalities include physical therapy targeting pericranial myofascial trigger points, electromyographic biofeedback, and stress reduction. Patients must be cautioned against frequent use of simple analgesics to prevent transition to medication-overuse headache.

3. Medication-Overuse Headache (MOH / Rebound Headache)

Medication-overuse headache is one of the most common and disabling conditions encountered in primary care headache medicine, affecting up to 1% to 2% of the general population and 30% to 50% of patients attending specialized headache clinics.

• ICHD-3 Diagnostic Criteria:
  1. Headache occurring on $\ge 15\text{ days per month}$ in a patient with a pre-existing primary headache disorder.
  2. Regular overuse of acute headache treatments for $>3\text{ months}$, defined as:
     • $\ge 10\text{ days per month}$ for ergotamines, triptans, opioids, or combination analgesics (e.g., butalbital-acetaminophen-caffeine [Fioricet], acetaminophen-aspirin-caffeine [Excedrin]).
     • $\ge 15\text{ days per month}$ for simple analgesics (acetaminophen, ibuprofen, naproxen).
• Pathophysiology: Chronic, repetitive receptor binding by acute rescue agents induces cellular tolerance, downregulation of 5-HT1B/1D receptors, upregulation of pronociceptive CGRP pathways, and suppression of endogenous endocannabinoid and opioid inhibitory networks. The patient enters a self-perpetuating cycle where wearing off of the acute medication provokes a rebound withdrawal headache, prompting further medication consumption.
• Clinical Management Protocol:
  • Patient Education: Validate the patient's suffering while clearly communicating the paradox: the medication used to abort the pain has become the primary mechanism sustaining the chronic headache.
  • Discontinuation of the Offending Agent: Immediate abrupt cessation is recommended for triptans, ergots, NSAIDs, and acetaminophen. In contrast, gradual outpatient tapering is mandatory for butalbital-containing compounds and opioids to avoid life-threatening withdrawal seizures or severe autonomic rebound.
  • Anticipate Withdrawal Rebound: Warn the patient that headaches will temporarily worsen for 2 to 10 days following discontinuation, frequently accompanied by nausea, insomnia, restlessness, and anxiety.
  • Bridge (Transition) Therapy: To alleviate withdrawal distress, prescribe a short-term bridge:
    • Oral Prednisone Taper: 60 mg daily for 3 days, tapered by 10-20 mg every 2 days over a 7- to 10-day course.
    • Scheduled Long-Acting NSAID: Naproxen 500 mg twice daily with gastroprotection (PPI) for 10 to 14 days (only if the overused agent was not an NSAID).
    • Antiemetics: Metoclopramide 10 mg or prochlorperazine 10 mg orally as needed.
  • Initiation of Preventive Therapy: Initiate effective evidence-based migraine prophylaxis (e.g., topiramate, CGRP monoclonal antibody, or OnabotulinumtoxinA) simultaneously with the withdrawal process rather than waiting for complete detoxification.

---

Trigeminal Neuralgia (Tic Douloureux)

Trigeminal neuralgia (TN) is an agonizing neuropathic disorder characterized by paroxysmal, unilateral facial pain. It has an incidence of approximately 4 to 13 per 100,000 person-years, with a slight female preponderance and peak onset after age 50.

                  PATHOPHYSIOLOGY & ANATOMY OF TRIGEMINAL NEURALGIA

   Superior Cerebellar Artery (SCA) Aberrant Loop (80-90%)
                         │
                         ▼
   Pulsatile Mechanical Compression of CN V at Root Entry Zone (REZ) in Prepontine Cistern
                         │
                         ▼
   Focal Demyelination of Large Myelinated A-β Sensory Fibers
                         │
                         ▼
   Ephaptic Transmission ('Cross-Talk') to Adjacent Nociceptive A-δ & C Fibers
                         │
                         ▼
   Innocuous Tactile Stimulus (Light Touch, Shaving, Wind) ──> Sudden, Violent Lancinating Paroxysm

Etiology & Pathophysiology

• Classical Trigeminal Neuralgia: In over 80% to 90% of cases, classical TN is caused by mechanical neurovascular compression of the trigeminal sensory root at the Root Entry Zone (REZ) in the prepontine cistern. In the vast majority of cases, the compressing vessel is an aberrant or ectatic loop of the superior cerebellar artery (SCA); less commonly, the anterior inferior cerebellar artery (AICA) or a petrosal vein is implicated.
• The Ephaptic 'Cross-Talk' Hypothesis: The REZ represents a transitional zone of anatomical vulnerability where peripheral Schwann cell myelination transitions to central oligodendroglial myelin. Chronic pulsatile vascular compression induces focal mechanical demyelination of heavily myelinated A-beta sensory fibers (which convey light touch). The close apposition of demyelinated membranes allows electrical charges to jump directly to neighboring unmyelinated and thinly myelinated A-delta and C nociceptive fibers via ephaptic transmission. Consequently, light tactile inputs directly ignite violent paroxysmal pain discharges.
• Secondary Trigeminal Neuralgia: In approximately 10% to 15% of cases, the condition is secondary to structural pathology:
  • Multiple Sclerosis (MS): Demyelinating plaque within the pontine trigeminal entry zone. Suspect in patients under 40 years of age or those presenting with bilateral facial pain.
  • Cerebellopontine Angle (CPA) Neoplasms: Meningioma, vestibular schwannoma, or epidermoid cyst compressing the trigeminal nerve root.

Clinical Manifestations

• Paroxysmal, Excruciating Pain: Sudden, unilateral, lancinating, sharp, electrical shock-like, or stabbing pain lasting from a fraction of a second up to 2 minutes. Pain attacks often occur in clusters throughout the day.
• Anatomical Distribution: Pain is strictly restricted to one or more sensory divisions of the trigeminal nerve (CN V). The maxillary division (V2) and mandibular division (V3) are involved in over 90% of cases (frequently together). The ophthalmic division (V1) is affected in $<5%$ of cases.
• Cutaneous Trigger Zones: Agonizing paroxysms are provoked by trivial, non-noxious mechanical stimulation of specific trigger zones on the face or oral cavity: light touch, brushing teeth, chewing, talking, shaving, washing the face, smiling, or a cold breeze.
• Refractory Period: Characteristically, each paroxysm is followed by a brief refractory interval lasting seconds to minutes during which mechanical stimulation cannot provoke another attack.
• Physical Examination: In classical trigeminal neuralgia, the cranial nerve examination is COMPLETELY NORMAL. Objective sensory loss (e.g., facial hypesthesia, loss of corneal reflex) or motor weakness of the muscles of mastication is an alarming red flag indicating secondary structural pathology (tumor or demyelinating disease).

Diagnostic Neuroimaging

Every patient with suspected trigeminal neuralgia must undergo high-resolution Magnetic Resonance Imaging (MRI) of the Brain with thin-slice 3D construct sequences (e.g., CISS or FIESTA) with and without IV gadolinium contrast. MRI evaluates for neurovascular compression at the root entry zone and rules out multiple sclerosis demyelinating plaques and CPA tumors.

Pharmacotherapy of Trigeminal Neuralgia

                  PHARMACOTHERAPY OF TRIGEMINAL NEURALGIA

   Agent                 Dosage & Titration                     Clinical Pearls & Mechanism   Monitoring & Toxicities
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Carbamazepine         Start 100-200 mg BID; titrate by       GOLD STANDARD FIRST-LINE;     CBC (aplastic anemia, agranulocytosis),
   (First-Line)          200 mg every 2-3 days to target        blocks voltage-gated Na+      electrolytes (SIADH/hyponatremia), LFTs.
                         600-1200 mg/day (max: 1200 mg/day)     channels; >80% initial relief HLA-B*1502 screening in Asian descent!
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Oxcarbazepine         Start 150-300 mg BID; titrate          First-line alternative;       Electrolytes (higher incidence of
   (First-Line)          by 300 mg every 3 days to target       equal efficacy, better        hyponatremia than carbamazepine);
                         1200-1800 mg/day in divided doses      tolerability, fewer drug DIs  somnolence, dizziness, ataxia.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Baclofen              Start 5-10 mg TID; titrate to          Second-line add-on agent;     Sedation, muscle weakness, confusion;
   (Add-on)              target 40-80 mg/day                    GABA-B receptor agonist;      avoid abrupt withdrawal (seizures,
                                                                synergistic with Na+ blockers hallucinations, delirium).
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Lamotrigine           Start 25 mg daily; slow titration      Second-line add-on agent;     Risk of severe cutaneous eruption /
   (Add-on)              over 6-8 weeks to 200-400 mg/day       blocks Na+ channels and       Stevens-Johnson syndrome with
                                                                inhibits glutamate release    rapid titration.
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

• Carbamazepine: First-line gold standard therapy, providing prompt relief in $>80%$ of patients. Mechanism: stabilizes the inactivated state of voltage-gated sodium channels, curbing high-frequency repetitive discharges.
  • Adverse Effects: Somnolence, dizziness, diplopia, ataxia, nausea, hyponatremia due to an SIADH-like effect, elevated transaminases, leukopenia, and rare but catastrophic aplastic anemia or agranulocytosis.
  • Pharmacogenomic Screening: The US FDA mandates screening for the HLA-B*1502 allele prior to starting carbamazepine in patients of Asian ancestry (Han Chinese, Taiwanese, Thai, Malaysian, Filipino, Indian). The HLA-B*1502 allele carries an extreme hazard ratio ($>100$) for developing life-threatening Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
  • Laboratory Monitoring: Baseline CBC, electrolytes, and hepatic transaminases, repeated at 2 to 4 weeks, 3 months, and periodically thereafter.
• Oxcarbazepine: Keto-derivative of carbamazepine acting as a prodrug for 10-monohydroxy metabolite (MHD). Equal clinical efficacy to carbamazepine with lower hepatic enzyme induction and fewer drug-drug interactions, but carries a higher risk of clinically significant hyponatremia.

Surgical Interventions for Trigeminal Neuralgia

Surgical consultation is indicated for patients with medically refractory pain, breakthrough paroxysms, or intolerable drug toxicities:

1. Microvascular Decompression (MVD / Jannetta Procedure):
   • Suboccipital retrosigmoid craniotomy to visualize the trigeminal root entry zone in the posterior fossa. The offending compressing artery (usually the SCA) is dissected away from the nerve and an inert Teflon felt sponge is interpositioned between the vessel and the nerve root.
   • Definitive Treatment: Achieves the highest long-term pain-free remission rate ($>70-80%$ at 5 to 10 years) without producing facial numbness or sensory loss. Operative mortality is $<0.5%$; risks include hearing loss (CN VIII injury), CSF leak, and cerebellar stroke.
2. Percutaneous Rhizotomy Procedures:
   • Radiofrequency thermocoagulation, glycerol rhizolysis, or percutaneous balloon microcompression performed via a needle inserted through the cheek into the foramen ovale to selectively injure trigeminal pain fibers in Meckel's cave. Effective alternative for older or frail patients unable to tolerate open craniotomy; trades pain relief for varying degrees of facial hypesthesia, dysesthesias, or corneal anesthesia (loss of corneal blink reflex with risk of neurotrophic keratitis).
3. Stereotactic Radiosurgery (Gamma Knife):
   • Highly focused, single-fraction ionizing radiation delivered to the trigeminal root entry zone. Non-invasive, outpatient procedure suitable for high-risk surgical candidates. Pain relief is delayed, taking 4 to 8 weeks to manifest.